Epigenetic Silencing of MiR-137 is an Early Event in Colorectal Carcinogenesis
Overview
Authors
Affiliations
Global downregulation of microRNAs (miRNA) is a common feature in colorectal cancer (CRC). Whereas CpG island hypermethylation constitutes a mechanism for miRNA silencing, this field largely remains unexplored. Herein, we describe the epigenetic regulation of miR-137 and its contribution to colorectal carcinogenesis. We determined the methylation status of miR-137 CpG island in a panel of six CRC cell lines and 409 colorectal tissues [21 normal colonic mucosa from healthy individuals (N-N), 160 primary CRC tissues and their corresponding normal mucosa (N-C), and 68 adenomas]. TaqMan reverse transcription-PCR and in situ hybridization were used to analyze miR-137 expression. In vitro functional analysis of miR-137 was performed. Gene targets of miR-137 were identified using a combination of bioinformatic and transcriptomic approaches. We experimentally validated the miRNA:mRNA interactions. Methylation of the miR-137 CpG island was a cancer-specific event and was frequently observed in CRC cell lines (100%), adenomas (82.3%), and CRC (81.4%), but not in N-C (14.4%; P < 0.0001 for CRC) and N-N (4.7%; P < 0.0001 for CRC). Expression of miR-137 was restricted to the colonocytes in normal mucosa and inversely correlated with the level of methylation. Transfection of miR-137 precursor in CRC cells significantly inhibited cell proliferation. Gene expression profiling after miR-137 transfection discovered novel potential mRNA targets. We validated the interaction between miR-137 and LSD-1. Our data indicate that miR-137 acts as a tumor suppressor in the colon and is frequently silenced by promoter hypermethylation. Methylation silencing of miR-137 in colorectal adenomas suggests it to be an early event, which has prognostic and therapeutic implications.
Bin Wan Mohd Nor W, Kwong S, Fuzi A, Said N, Jamil A, Lee Y Int J Mol Med. 2025; 55(3).
PMID: 39820715 PMC: 11759585. DOI: 10.3892/ijmm.2025.5487.
miR-137: a potential therapeutic target for lung cancer.
Liu S, Ruan Y, Chen X, He B, Chen Q Front Cell Dev Biol. 2024; 12:1427724.
PMID: 39247624 PMC: 11377224. DOI: 10.3389/fcell.2024.1427724.
BharathwajChetty B, Sajeev A, Vishwa R, Aswani B, AlQahtani M, Abbas M Cancer Metastasis Rev. 2024; 43(1):321-362.
PMID: 38517618 DOI: 10.1007/s10555-024-10171-0.
Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice.
Ascrizzi S, Arillotta G, Grillone K, Carida G, Signorelli S, Ali A Cancers (Basel). 2023; 15(15).
PMID: 37568746 PMC: 10417124. DOI: 10.3390/cancers15153930.
Pimenta R, Mioshi C, Goncalves G, Candido P, Camargo J, Guimaraes V Int J Mol Sci. 2023; 24(11).
PMID: 37298588 PMC: 10253647. DOI: 10.3390/ijms24119633.